Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study

Bertuzzi, Michela; Marelli, Cristina; Bagnati, Renzo; Colombi, Alessandro; Fanelli, Roberto; Saieva, Calogero; Ceroti, Marco; Bendinelli, Benedetta; Caini, Saverio; Airoldi, Luisa; Palli, Domenico

doi:10.1186/s12885-015-1058-7

Table 2 Candidate biomarkers selected for LC-SRM-MS analysis

From: Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study

Protein name	UniProt Entry name	FC^a	VIP^b	Protein function^c	Proteotypic peptide^d	Peptide molecular weight	Transitions^f		CE (V)^h
							Precursor ion	Product ion
							m/z^g	m/z^g
Apoliprotein C-II	APOC2	2.44	0.94	Lipid transport	TYLPAVDEK	1034.5	518.3	771.4	25
Apoliprotein C-II	APOC2	2.44	0.94	Lipid transport	TYLPAVDEK	1034.5	518.3	658.34	25
Clusterin	CLU	1.32	1.63	Complement pathway, innate immunity	TLLSNLEEAK	1118.8	559.4	790.4	20
Clusterin	CLU	1.32	1.63	Complement pathway, innate immunity	TLLSNLEEAK	1118.8	559.4	903.5	20
Complement C4-B	CO4-B	1.08	1.57	Complement pathway, innate immunity	VGDTLNLNLR	1113.8	557.9	629.4	15
Complement C4-B	CO4-B	1.08	1.57	Complement pathway, innate immunity	VGDTLNLNLR	1113.8	557.9	742.5	15
Complement Component C9	CO9	1.31	1.65	Complement activation, classical pathway	VVEESELAR	1030.5	516.27	704.35	25
Complement Component C9	CO9	1.31	1.65	Complement activation, classical pathway	VVEESELAR	1030.5	516.27	833.4	25
Alpha-2-HS-glycoprotein (Fetuin A)	FETUA	−1.14	1.46	Acute-phase response	HTLNQIDEDK	1196.6	598.9	845.4	20
Alpha-2-HS-glycoprotein (Fetuin A)	FETUA	−1.14	1.46	Acute-phase response	HTLNQIDEDK	1196.6	598.9	958.2	20
Mannan-binding lectin serine-protease	MASP2	1.72	0.50	Lectin complement pathway, innate immunity	AGYVLHR^e	814.4	408.23	425.8	15
Mannan-binding lectin serine-protease	MASP2	1.72	0.50	Lectin complement pathway, innate immunity	AGYVLHR^e	814.4	408.23	312.9	15
Mannose-binding protein C	MBL2	3.30	0.62	Lectin complement pathway, innate immunity	SPDGDSSLAASER	1290.8	646.9	533.3	25
Mannose-binding protein C	MBL2	3.30	0.62	Lectin complement pathway, innate immunity	SPDGDSSLAASER	1290.8	646.9	733.38	25
N-acetylmuramoyl-L-alanine amidase	PGRP2	1.62	1.03	Petidoglycan digestion, innate immunity	TFTLLDPK	933.5	466.67	686.4	25
N-acetylmuramoyl-L-alanine amidase	PGRP2	1.62	1.03	Petidoglycan digestion, innate immunity	TFTLLDPK	933.5	466.67	585.4	20
Bovine Fetuin	FETUA-B	Internal Standard			TPIVGQPSIPGGPVR	1474.8	737.9	582.3	25
Bovine Fetuin	FETUA-B	Internal Standard			TPIVGQPSIPGGPVR	1474.8	737.9	879.5	25

^aFC, fold change of protein plasma level in the global proteome study of the EPIC population.
^bVIP, variable importance in the projection, PLS-DA analysis (global proteome study of the EPIC population).
^cDeduced from UniProt database.
^dAmino acid sequence of the peptide selected for quantitation by LC-SRM-MS.
^eAlthough this peptide has only seven amino acid residues, it was selected for SRM analysis because it gave the best response.
^fThe transition used for quantitation is shown in bold type; the other transition was used to maximise the specificity of the method.
^gm/z, mass to charge ratio of the selected peptide.
^hCE, collision energy.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us